Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company focused on inflammatory diseases like asthma and COPD, will participate in a fireside chat at the H.C. Wainwright 4th Annual BioConnect Investor Conference on May 19, 2026. The company is advancing rademikibart, a next-generation antibody targeting IL-4Rα, currently in global clinical trials for acute exacerbations of asthma and COPD. Connect Biopharma has licensed rademikibart to Simcere Pharmaceutical for Greater China, with potential milestone payments up to $110 million and royalties on sales. Investors can access the live webcast and archived replay on the company's website.
Bitcoin miners are experiencing declining revenue as the network's hash rate and mining difficulty fall, reflecting a shift of miners into AI infrastructure. Despite this stress, miners are accumulating Bitcoin, with reserves increasing by 1%, signal...
Lululemon invested in Syntetica's $30 million Series A funding to support its innovative recycling of Nylon 6 and Nylon 6,6, materials difficult to separate and reuse in textile waste. This move aligns with growing industry demand for sustainable, co...
Ethereum futures long positions among top traders increased by over 3 percentage points across both USDT- and coin-margined markets, indicating a broad-based shift in short-term sentiment. This rise suggests heightened attention on ETH compared to ot...
NVIDIA announced that leading Japanese companies in robotics and manufacturing are adopting its Cosmos, Isaac, Metropolis, and Jetson platforms to accelerate AI-powered intelligent machines across industries. The new Cosmos 3 Edge model enables real-...
Oil prices are rising sharply due to renewed US naval blockades on Iranian shipping and increased tensions in the Strait of Hormuz, a critical oil transit route. Brent crude is holding above $85 and WTI above $80, with forecasts suggesting WTI could ...
